What markers track genomic instability?
A research-supply overview of the markers and molecular readouts used to track genomic instability, drawing on evidence spanning NMNAT-1/NAD+ biology, somatotroph adenoma pathogenesis, surgical stress trials, and biomark
Genomic instability is the umbrella term for the accumulation of DNA damage, replication errors, and chromosomal rearrangements that exceed a cell's repair capacity. In the research literature it is tracked through a set of markers rather than a single analyte: DNA damage foci and repair-pathway readouts, chromosomal aberration and aneuploidy measures, micronucleus formation, and the downstream senescence-associated secretory phenotype (SASP) that follows sustained damage. The evidence block for this page does not supply a single sequence, formula, or molecular weight for "genomic instability" as a compound, because it is a process rather than a molecule; the identifiers that appear in the evidence belong to the individual markers and pathways discussed below.
The work centres on the NAD+-dependent nuclear biosynthetic and DNA-repair axis, and on the receptor and signalling families that sit upstream of proliferative and stress responses in the tissues studied.
Research Studies
NMNAT-1 and nuclear NAD+ homeostasis in DNA repair and neuronal maintenance
Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyses the final step in NAD+ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family. NAD+ is described as a fundamental metabolic cofactor and signalling molecule supporting redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation, and neuronal maintenance. Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, but the causal node and the limiting compartment differ across tissues and disease states. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited disease [1].
NAD+ decline and genomic instability in the menopause context
A review of NAD+ and its anti-aging effects in the context of longevity and menopause reports that menopause is a complex biological condition associated with progressive estrogen depletion and increased susceptibility to several age-associated disorders. Among the biological mechanisms discussed in that context are mitochondrial dysfunction, oxidative stress, chronic inflammation, genomic instability, and immunosenescence [5].
Ovarian aging and genomic instability as an intrinsic cellular defect
A review of ovarian aging and systemic health outlines intrinsic ovarian cellular defects including genomic instability, epigenetic shifts, and mitochondrial and proteostasis damage. Those defects are described as potentially triggering SASP-related inflammaging and fibrosis via the ovarian-systemic axis [6].
Senescence, SASP and inflammaging as downstream readouts
A review of the complosome as a modulator of cellular senescence, aging, and age-related diseases describes aging as progressive physiological decline with accumulation of senescent cells that drive chronic inflammaging through the SASP. The complement system, traditionally viewed as a systemic extracellular defence mechanism, is now recognised as an essential intracellular component in this setting [7].
Senotherapeutic strategies and cell-cycle arrest pathways in ovarian aging
A review of senotherapeutic strategies for ovarian aging reports that ovarian aging manifests as progressive depletion of the primordial follicle reserve and declining oocyte quality, culminating in menopause and associated systemic comorbidities. Cellular senescence is described as a central driver, exerting effects through cell-cycle arrest pathways and a proinflammatory senescent phenotype [8].
GHRH and somatostatin receptor signalling in somatotroph adenoma pathogenesis
In nonfamilial somatotroph adenomas, excess growth hormone production leading to acromegaly most commonly emanates from an adenomatous pituitary somatotroph. Somatotroph cells express cognate G protein-coupled receptors for both hypothalamic stimulatory GH-releasing hormone (GHRH) and inhibitory somatostatin. Understanding the pathogenesis of these adenomas is framed as a route to clarifying how biologic behaviour affects acromegaly treatment outcomes [2].
Alpha ketoglutarate and the surgical stress response in older CABG patients
The AEGIS trial addresses coronary artery bypass grafting, performed in approximately 400,000 patients in the United States each year, as one of the most common major surgeries in older patients. CABG invokes a massive surgical stress response, with systemic epinephrine increasing 33-fold and norepinephrine increasing 3-fold. Local tissue injury produces sterile inflammation with release of damage-associated molecular patterns (DAMPs), which activate neutrophils and bring a cascade of cytokines, complement, and coagulation changes; nociceptor activation produces a neurometabolic response involving the sympathetic nervous system and the hypothalamus-pituitary axis [3].
Ki67 and receptor biomarkers in early triple negative breast cancer
Breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide, and is distinguished into subtypes by clinical, molecular, and genetic characteristics that differ in disease progression, treatment response, and rate of metastasis. Treatment decisions are based mainly on the presence or absence of established prognostic and predictive biomarkers — principally the estrogen (ER) and progesterone (PR) hormone receptors and the human epidermal growth factor receptor 2 (HER2) oncoprotein — in correlation with the ki67 proliferation index. Tumor size, histological grade, and lymph node status are also used [4].
Comparing marker classes across the evidence
| Marker or readout | What it indexes | Model or population in the evidence |
|---|---|---|
| NMNAT-1 / nuclear NAD+ | Final step of NAD+ biosynthesis; DNA repair and chromatin regulation support | Human genetic evidence in inherited disease; brain aging and neurodegeneration contexts [1] |
| Genomic instability (as a listed mechanism) | Accumulated DNA damage within a multi-mechanism aging panel | Menopause and longevity review context [5] |
| Genomic instability (as an intrinsic ovarian defect) | Ovarian cellular defect upstream of SASP-related inflammaging | Ovarian aging and systemic health review [6] |
| SASP / inflammaging | Downstream secretory consequence of senescent cell accumulation | Aging and age-related disease review [7] |
| Cell-cycle arrest pathways | Senescence driver in follicle depletion and oocyte quality decline | Ovarian aging senotherapeutics review [8] |
| Ki67 proliferation index | Proliferative fraction, used alongside ER, PR, HER2 | Early triple negative breast cancer patients [4] |
Where the evidence is animal-only or in vitro
The evidence block for this page does not supply animal-only or in vitro findings for the markers listed above; the cited items are reviews, human genetic evidence, and registered clinical studies. Where a claim is not supported by the evidence block, it has been left out.
If you are reading this for personal health reasons
The materials described here are sold for laboratory research use only. We do not provide dosing, diagnostic, or medical guidance, and nothing on this page should be read as a recommendation for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD+ Homeostasis in Neuroprotection and Aging
- [2] Pathogenesis of nonfamilial somatotroph adenomas
- [3] Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)
- [4] Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy
- [5] Nicotinamide Adenine Dinucleotide and Its Anti-aging Effects in the Context of Longevity and Menopause
- [6] Ovarian aging and systemic health: Mechanisms and emerging intervention strategies
- [7] Complosome as a key modulator of cellular senescence, aging and age-related diseases
- [8] Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives